ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This registered randomized trial tests whether adding a specific intradermal acupuncture method to standard mesalazine treatment helps people with mild–moderately active ulcerative colitis reach clinical remission.
Results could be relevant for patients considering complementary therapies alongside anti-inflammatory medication.
Who Should Pay Attention
Adults with ulcerative colitis on mesalazine; clinicians and researchers interested in complementary therapies for IBD.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment66 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This ClinicalTrials.gov record describes a randomized, interventional study testing whether adding intradermal “thumbtack” acupuncture to stable mesalazine therapy improves outcomes in adults with mild–moderately active ulcerative colitis over 12 weeks.
Participants continue a stable dose of mesalazine while receiving either embedded intradermal needles at specific acupoints (verum) or needle-free placebo patches at non-acupoints (sham); colonoscopy and clinical scores are used to assess the primary endpoint (clinical remission at week 13–16).
The trial is recruiting at Tongji Hospital in Wuhan, China, plans to enroll 66 adults, and specifies frequent self-stimulation of embedded needles and weekly replacement for 12 weeks. Key inclusion/exclusion rules, the Mayo-based remission definition, and requirement for two colonoscopies are listed in the registry record.
The record also states an intent to explore potential mechanisms, and the design uses mesalazine as background therapy so the study evaluates acupuncture’s additive effect, not acupuncture alone.
Keep In Mind
Registry entry describes study design, eligibility, and planned outcomes but does not report results. The intervention is evaluated as an add-on to stable mesalazine therapy; colonoscopies are required pre- and post-treatment. SummaryConfidence":"high"
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorQin Yu
Trial IDNCT07389824
Study typeInterventional
Trial phaseNA
Enrollment66 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 25, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...